POS0411 Characteristics at diagnosis associated to glucocorticoid use at 2 years for those with polymyalgia rheumatica - A national study of England

Current guidelines recommend glucocorticoids (GCs) for the treatment of Polymyalgia Rheumatica (PMR) for 1 to 2 years. Surveys and administrative datasets from many European countries and the USA show that approximately 50% of patients are on GCs for at least 2 years. A previous study looking at individuals with PMR and GC dependence, found the neutrophil-lymphocyte ratio (NLR) at diagnosis to be associated with GC dependency.